Published in Pediatr Blood Cancer on February 15, 2013
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol (2002) 2.17
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood (2002) 2.06
Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. J Am Acad Dermatol (1999) 1.50
Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica (2010) 1.45
Leukemia cutis. Dermatol Clin (1994) 1.31
Leukemia cutis - epidemiology, clinical presentation, and differential diagnoses. J Dtsch Dermatol Ges (2011) 1.30
What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant (2003) 1.22
Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood (2006) 1.18
Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm. Am J Clin Pathol (2012) 1.07
CD4+/CD56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol (2007) 1.03
Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome. Leuk Lymphoma (2006) 0.92
CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom (2009) 0.86
Childhood CD4+/CD56+ hematodermic neoplasm: case report and review of the literature. Haematologica (2006) 0.84
An unusual case of CD4+ CD7+ CD56+ acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia. Eur J Haematol (2003) 0.84
CD4+/CD56+ hematodermic neoplasm: blastic NK cell lymphoma in a 6-year-old child: report of a case and review of literature. J Pediatr Hematol Oncol (2007) 0.83
Plasmacytoid dendritic cell leukemia in children. J Pediatr Hematol Oncol (2009) 0.82
Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leuk Res (2002) 0.81
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Planning cancer control in Latin America and the Caribbean. Lancet Oncol (2013) 8.43
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
The tumor lysis syndrome. N Engl J Med (2011) 4.29
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol (2008) 3.34
Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol (2009) 2.97
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol (2010) 2.63
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res (2010) 2.51
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood (2012) 2.39
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet (2009) 2.37
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood (2009) 2.36
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood (2005) 2.24
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet (2005) 1.94
Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA (2002) 1.93
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer (2005) 1.93